Exploring the role of PRDX4 in the development of uterine corpus endometrial carcinoma

Peroxicedoxin 4 (PRDX4), a member of the peroxicedoxins (PRDXs), has been reported in many cancer-related studies, but its role in uterine corpus endometrial carcinoma (UCEC) is not fully understood. In the present study, we found that PRDX4 was highly expressed in UCEC tissues and cell lines throug...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2024-01, Vol.41 (2), p.48-48, Article 48
Main Authors: Lei, Ping, Yu, Liting, Sun, Xiaoli, Hao, Junmei, Shi, Wenning, Sun, Haojie, Guo, Xiangji, Jia, Xikang, Liu, Tianli, Zhang, Dao-Lai, Li, Lianqin, Wang, Hongmei, Xu, Cong
Format: Article
Language:English
Subjects:
Cell Line
Computational Biology
Disease Progression
Endometrial cancer
Endometrial Neoplasms - genetics
Female
Hematology
Humans
Internal Medicine
Medicine
Medicine & Public Health
Oncology
Original Paper
Pathology
Peroxiredoxins - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peroxicedoxin 4 (PRDX4), a member of the peroxicedoxins (PRDXs), has been reported in many cancer-related studies, but its role in uterine corpus endometrial carcinoma (UCEC) is not fully understood. In the present study, we found that PRDX4 was highly expressed in UCEC tissues and cell lines through the combination of bioinformatics analysis and experiments, and elevated PRDX4 levels were associated with poor prognosis. Knockdown of PRDX4 significantly blocked the proliferation and migration of the UCEC cell line Ishikawa and reduced degree of cell confluence. These findings highlight the oncogenic role of PRDX4 in UCEC. In addition, genes that interact with PRDX4 in UCEC were MT-ATP8, PBK, and PDIA6, and we speculated that these genes interacted with each other to promote disease progression in UCEC. Thus, PRDX4 is a potential diagnostic biomarker for UCEC, and targeting PRDX4 may be a potential therapeutic strategy for patients with UCEC.
ISSN:1559-131X
1357-0560
1559-131X
DOI:10.1007/s12032-023-02265-6